Cambridge, Mass., USA – Jounce Therapeutics, Inc., a company developing novel cancer immunotherapies, announced the appointment of Kim Drapkin to the position of chief financial officer. [break]
Ms. Drapkin brings to Jounce more than 20 years of experience working with private and publically traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital and leading strategic financial planning.
Prior to joining Jounce, Ms. Drapkin owned a financial consulting firm where she served
as the interim chief financial officer for numerous early stage biotechnology companies, including Jounce. Additional clients included Eleven Biotherapeutics, Inc., NinePoint
Medical, Inc., Blueprint Medicines Corporation, Warp Drive Bio LLC, Edimer
Pharmaceuticals and Voyager Therapeutics, Inc.
Previously Ms. Drapkin was chief financial officer at EPIX Pharmaceuticals. Prior to EPIX, she was at Millennium Pharmaceuticals where she spent ten years in roles of increasing responsibility within the finance organization.
Ms. Drapki - September 16, 2015, Cambridge, Mass., USA – Jounce Therapeutics, Inc., a company developing novel cancer immunotherapies, announced the appointment of Kim Drapkin to the position of chief financial officer.
Article continues below
]
Ms. Drapkin brings to Jounce more than 20 years of experience working with private and publically traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital and leading strategic financial planning.
Prior to joining Jounce, Ms. Drapkin owned a financial consulting firm where she served
as the interim chief financial officer for numerous early stage biotechnology companies, including Jounce. Additional clients included Eleven Biotherapeutics, Inc., NinePoint
Medical, Inc., Blueprint Medicines Corporation, Warp Drive Bio LLC, Edimer
Pharmaceuticals and Voyager Therapeutics, Inc.
Previously Ms. Drapkin was chief financial officer at EPIX Pharmaceuticals. Prior to EPIX, she was at Millennium Pharmaceuticals where she spent ten years in roles of increasing responsibility within the finance organization. ■